Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MC1R | Q01726 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649409 | 0.81 | MTNR1A (0.57) | CA2MAPK1TDP1CYP1A2CYP2C19 | |
| SCHEMBL6006425 | 0.79 | KMT2A (0.46) | CA2MEN1MAPTKMT2AMC5R | |
| SCHEMBL6008064 | 0.77 | MC5R (0.70) | CA2MEN1MAPTKMT2AMC5R | |
| SCHEMBL19144969 | 0.75 | CA2 (0.56) | CA2MEN1MAPTKMT2AMC5R | |
| SCHEMBL6007605 | 0.75 | TDP1 (0.59) | CA2MEN1KMT2ATDP1CYP2C19 | |
| SCHEMBL6007598 | 0.74 | MAOA (0.40) | MAPTTDP1HPGD | |
| SCHEMBL681401 | 0.74 | IFNAR1 (0.66) | CA2MEN1MAPTKMT2AMC5R | |
| SCHEMBL19990735 | 0.74 | CA2 (0.55) | CA2MEN1MAPTKMT2AMC5R | |
| SCHEMBL5321295 | 0.74 | IFNAR1 (0.66) | CA2MEN1MAPTKMT2AMC5R | |
| SCHEMBL20495649 | 0.74 | HPGD (0.69) | CA2MEN1MAPTKMT2AMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2088151-A1 | GOLD COMPLEX, METHOD FOR PRODUCTION OF THE GOLD COMPLEX, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT ELEMENT USING THE GOLD COMPLEX | Ube Industries, Ltd. (JP) | 2009-08-12 | — | — | EP | claimed |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-06-12 | — | — | US | claimed |
| EP-1793843-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006039527-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-13 | — | — | WO | claimed |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024118776-A1 | MATERIALS AND METHODS FOR APTAMER SELECTION | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-118064441-A | Methods of producing aptamers with improved dissociation rates | 私募蛋白质体运营有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4323524-A1 | NUCLEIC ACID COMPOUNDS THAT BIND CORONAVIRUS PROTEINS | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-116334088-A | Compositions and methods for detecting microorganisms | 私募蛋白质体运营有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | SOMALOGIC OPERATING CO., INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230093170-A1 | Nucleic Acid Compounds for Binding to Complement Component 3 Protein | SOMALOGIC OPERATING CO., INC. (US) | 2023-03-23 | — | — | US | disclosed |
| EP-0865425-A1 | AMINO ACID DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHODS OF PRODUCING THEM | Dr. Karl Thomae GmbH (DE) | 1998-09-23 | — | — | EP | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| WO-1997019913-A1 | AMINO ACID DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHODS OF PRODUCING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0696586-A1 | SERINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | APOL1, UFL1, ACSL3 | CA2 3285/4885MEN1 4433/4885MAPT 3415/4885 |
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | MSTN, S100A11, IGF2BP1 | CA2 2173/4885MEN1 1586/4885MAPT 3786/4885 |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | ACP1, PPM1D, LASP1 | CA2 1144/4885MEN1 4312/4885MAPT 4810/4885 |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SARS1, RNGTT, PABPC1 | CA2 1611/4885MEN1 4651/4885MAPT 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.